Mechanisms of resistance to active state selective tri-complex RAS inhibitors
Ben Sang(Memorial Sloan Kettering Cancer Center), Piro Lito(Memorial Sloan Kettering Cancer Center), David S. Hong(The University of Texas MD Anderson Cancer Center), Jacqueline A.M. Smith(Revolution Medicines (United States)), Ignacio Garrido‐Laguna(University of Utah), Arvin C. Dar(Memorial Sloan Kettering Cancer Center), Fengping Hu(East China Jiaotong University), Rona Yaeger(Memorial Sloan Kettering Cancer Center), Alexander I. Spira(Virginia Cancer Specialists), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Brian M. Wolpin(Harvard University), Salman R. Punekar(NYU Langone Health), Ling Feng Ye(Memorial Sloan Kettering Cancer Center), Antonio Cuevas-Navarro(Memorial Sloan Kettering Cancer Center), Shijie Fan(Memorial Sloan Kettering Cancer Center), Ethan Ahler(Revolution Medicines (United States)), Alberto Vides(Memorial Sloan Kettering Cancer Center), Kevin K. Lin(Revolution Medicines (United States)), A Washington(Memorial Sloan Kettering Cancer Center), Diego J. Rodriguez(Memorial Sloan Kettering Cancer Center), Yasin Pourfarjam(Memorial Sloan Kettering Cancer Center), Zheng Qing Fu(Hainan University)
Cited by 10
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k